Reuters logo
BRIEF-Tonix Pharmaceuticals to commence "honor" study this quarter
March 7, 2017 / 12:21 PM / 7 months ago

BRIEF-Tonix Pharmaceuticals to commence "honor" study this quarter

March 7 (Reuters) - Tonix Pharmaceuticals Holding Corp

* Tonix Pharmaceuticals Holding says will commence in this quarter “honor” study, a 12-week phase 3 clinical study evaluating TNX-102 SL, 5.6 mg, in military-related PTSD

* Tonix Pharmaceuticals Holding says interim analysis of honor study is expected in first half of 2018, topline results are expected in second half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below